---
layout: single
title: Joint Development Project Proposal with Seoul National University Bundang Hospital (SNUBH)
permalink: /snubh/
toc: true
toc_label: "ToC"
toc_icon: "cog"
toc_sticky: true
---

<head>
	<link rel="stylesheet" href="/resource/styles.css">
</head>

<h1 id="short-proposal">
	Short proposal
</h1>

스탠포드 의대에서 시작된 Erudio Bio는 AI 기반 플랫폼을 통해 하나의 생물학적 샘플에서 기존 기술보다 1,000배 많은 데이터를 추출할 수 있어
8천억 달러 규모의 맞춤형 의료 시장에 새로운 혁신을 일으키고 있습니다.
첨단 반도체 공정을 활용한 multi-omic multiplexing 분석 기술은 세계 유일의 기술이면
현재 시장을 주도하는 기업들보다 월등히 뛰어난 정확도와 비용 효율성을 자랑합니다.
이를 통해 병원과 고객들은 더욱 정확하고 경제적인 서비스를 제공받을 수 있습니다.
현재 이 혁신적인 기술은 미국, 유럽, 중국 등에서 21개의 특허권을 확보하고 있습니다.

Erudio Bio, Inc.는 서울대학교 분당병원과
암 바이오마커 및 백신 관련 항체의 탐지 및 스크리닝을 중심으로 한 공동 개발 프로젝트를 제안하는 바입니다.
130여개의 병원으로 이루어져 있는 상하이 병원 네트워크와의 성공적인 협력에서 얻은 경험을 바탕으로,
SNUBH와의 협력에서도 유사한 방법론을 적용할 것입니다.
이 프로젝트는 우리의 첨단 시약과 검증된 프로토콜을 활용하여 민감하고
정확한 검사법을 개발하는 것을 목표로 합니다.
초기 단계에서는 인공 생물학적 매트릭스를 사용하여 귀중한 임상 샘플을 보존하며,
이후 임상 적용을 위해 과거 데이터를 공유하고 검증할 예정입니다.
공동 연구 결과를 학술지에 발표하여 협력의 성과를 입증할 계획이면
기술 이전을 통해 우리의 독점 검사법 기술과 시약을 SNUBH에 전달할 것입니다.
저희는 수검자 200명 기준 2~3억 연구비 예으로 공동연를 제안합니다.
이에 추가적인 논의를 통해 구체적인 협력 방안을 마련하고자 합니다.

<p>
회사 homepage: <a href="https://sungheeyun-erudio.github.io">https://sungheeyun-erudio.github.io</a>
<br>
구처적 Joint Development Proposal: <a href="https://sungheeyun-erudio.github.io/snubh">https://sungheeyun-erudio.github.io/snubh</a>
</p>



<h1 id="proposal-letter">
	Joint development project proposal
</h1>

Dear SNUBH,

We
at [Erudio Bio, Inc.]({{ site.baseurl }}/)
are excited to propose a Joint Development Project with Seoul National University Bundang Hospital, focusing on the detection and screening of cancer biomarkers and/or antibodies necessary for vaccination.

Following our successful discussions and preliminary agreements with Shanghai Hospital, we are keen to extend our expertise in assay development to SNUBH. Our recent collaboration involved the development of assays for uveitis using a phased approach, initially focusing on a subset of targets to streamline technology transfer and expedite publication processes. We propose a similar methodology where we begin with identifying key cancer biomarkers or vaccination-related antibodies, e.g., hepatitis, allowing for an efficient development cycle and early data publication.

Key aspects of our proposal include:

- Assay Development: Utilizing our advanced reagents and established protocols, we aim to develop sensitive and specific assays. We would start with a smaller panel of biomarkers or antibodies to ensure thorough validation and optimization, similar to our approach with Shanghai Hospital. This includes the use of artificial biological matrices during initial stages to conserve precious clinical samples.
- Data Sharing and Validation: We will share historical data on assay performance in various matrices, including test range, Limit of Detection (LOD), linearity, and inhibition percentages, to facilitate a smooth transition into clinical application.
- Joint Publication: A crucial aspect of our partnership will be the preparation and submission of a joint publication detailing our findings. This publication will serve as a testament to our collaborative efforts and the advancements made in cancer biomarker detection.
- Technology Transfer: To ensure the success of our project, we plan to transfer our proprietary assay technology and reagents to SNUBH. This includes sharing the precise procedures and protocols required for optimal results.
- Intellectual Property and Commercial Rights: The terms of intellectual property rights, commercialization, and publication will be clearly outlined in the Joint Development Agreement to ensure mutual benefit and protection.
- Timeline and Milestones: We propose to set a clear timeline, with defined milestones for assay development, validation, and subsequent clinical testing phases, ensuring that all parties are aligned on project expectations and deliverables.

We believe that this collaboration will not only advance diagnostic capabilities at SNUBH but also contribute significantly to global health by enhancing early detection and management strategies for cancer and infectious diseases. 

We are eager to discuss this proposal further and explore how we can tailor our joint efforts to meet SNUBH's specific needs and research interests.

Best regards,

<p>
Sunghee Yun
<br>
Co-founder and CTO
<br>
Erudio Bio, Inc.
</p>

<h1 id="erudio-intro">
	Brief intro to Erudio Bio, Inc.
</h1>


[Erudio Bio, Inc.]({{ site.baseurl }}/) is revolutionizing the economics of medicine with an AI enabled platform that can generate 1000x more data from a single biological sample than the market leading technology to make an impact on the $800B personalized medicine market. We stand to rapidly build shareholder value upon 16 years of previous work.
Erudio’s dynamic force spectroscopy was birthed at Stanford School of Medicine and the technology was validated by Analog Devices, a $90B semi company, resulting in a partnership.
Erudio began working with a large foreign hospital system serving 83M patient visits per year.

Here are a few highlights about the business:

- AI enhanced semiconductor chip-based medical data platform from Stanford
- Technology risk removed from 16 years of previous work evaluated by Analog Devices
- Product-market-fit with large foreign hospital system

<h1 id="erudio-intro">
	Erudio Bio, Inc. IR slides
</h1>

<a href="/resource/IR/2024_10_13_Erudio Bio 12.5.5.pdf">IR slides</a>
